HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
0 hedge funds and large institutions have $0 invested in HTG Molecular Diagnostics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 12 closing their positions.
2.71% less ownership
Funds ownership: 2.71% → 0% (-2.7%)
100% less funds holding
Funds holding: 12 → 0 (-12)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $67.3K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 12
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$39.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$14K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$4K |
| 4 |
BlackRock
New York
|
-$3.48K |
| 5 |
Morgan Stanley
New York
|
-$2.39K |
HTGM Hedge Fund Activity: Q2 2023 in Review
0 of the 6,388 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2023, worth a combined $0 — down 100% from $67.3K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HTGM and 0 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $39.7K sold.
- 0 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2023, down from 12 in Q1 2023.
- Funds reported $0 of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2023 and 12 closed out, a net change of -12 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2023 was Vanguard Group, an estimated $39.7K sold.
Based on aggregated 13F filings for Q2 2023.